Wedbush Lowers Earnings Estimates for Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Wedbush reduced their Q2 2025 earnings per share estimates for Neurocrine Biosciences in a report released on Wednesday, April 16th. Wedbush analyst L. Chico now expects that the company will earn $1.11 per share for the quarter, down from their previous estimate of $1.50. Wedbush currently has a “Outperform” rating and a $147.00 target price on the stock. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $4.28 per share. Wedbush also issued estimates for Neurocrine Biosciences’ Q4 2025 earnings at $1.21 EPS, FY2025 earnings at $4.57 EPS, Q4 2026 earnings at $1.89 EPS, FY2026 earnings at $6.64 EPS, FY2027 earnings at $11.75 EPS, FY2028 earnings at $13.73 EPS and FY2029 earnings at $15.41 EPS.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Thursday, February 6th. The company reported $1.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%.

A number of other research firms also recently issued reports on NBIX. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Neurocrine Biosciences in a research report on Tuesday, February 11th. They set a “hold” rating and a $138.00 target price on the stock. UBS Group cut their price objective on shares of Neurocrine Biosciences from $154.00 to $137.00 and set a “buy” rating on the stock in a research report on Friday, April 4th. Royal Bank of Canada raised Neurocrine Biosciences from a “sector perform” rating to an “outperform” rating and decreased their target price for the company from $138.00 to $137.00 in a research report on Monday, April 14th. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th. Finally, William Blair reissued an “outperform” rating on shares of Neurocrine Biosciences in a research note on Friday, February 7th. Three equities research analysts have rated the stock with a hold rating, twenty have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences has an average rating of “Moderate Buy” and an average target price of $161.86.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock opened at $101.38 on Friday. The stock has a market capitalization of $10.03 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 0.77 and a beta of 0.33. Neurocrine Biosciences has a 52-week low of $84.23 and a 52-week high of $157.98. The stock’s 50 day moving average price is $108.35 and its two-hundred day moving average price is $122.40.

Neurocrine Biosciences announced that its board has initiated a stock repurchase plan on Friday, February 21st that allows the company to repurchase $500.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 4.2% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other Neurocrine Biosciences news, CEO Kyle Gano sold 1,541 shares of Neurocrine Biosciences stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $152.87, for a total value of $235,572.67. Following the sale, the chief executive officer now owns 136,778 shares of the company’s stock, valued at approximately $20,909,252.86. The trade was a 1.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Julie Cooke sold 1,740 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.89, for a total transaction of $266,028.60. Following the transaction, the insider now directly owns 18,202 shares of the company’s stock, valued at $2,782,903.78. This represents a 8.73 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 167,906 shares of company stock valued at $24,671,530. Insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Neurocrine Biosciences

Several institutional investors have recently bought and sold shares of NBIX. Vanguard Group Inc. increased its position in Neurocrine Biosciences by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 10,119,641 shares of the company’s stock worth $1,381,331,000 after buying an additional 122,681 shares during the last quarter. Dodge & Cox increased its holdings in Neurocrine Biosciences by 134.2% in the 4th quarter. Dodge & Cox now owns 3,016,425 shares of the company’s stock worth $411,742,000 after acquiring an additional 1,728,605 shares during the last quarter. AQR Capital Management LLC raised its stake in Neurocrine Biosciences by 2.9% in the 4th quarter. AQR Capital Management LLC now owns 1,896,891 shares of the company’s stock valued at $258,926,000 after acquiring an additional 53,610 shares during the period. Geode Capital Management LLC lifted its holdings in Neurocrine Biosciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 1,875,062 shares of the company’s stock valued at $255,523,000 after purchasing an additional 15,830 shares during the last quarter. Finally, Wellington Management Group LLP boosted its position in Neurocrine Biosciences by 102.9% during the fourth quarter. Wellington Management Group LLP now owns 1,457,425 shares of the company’s stock worth $198,939,000 after purchasing an additional 739,199 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.